SciVision Biotech Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 3/6

SciVision Biotech kazançlarla iyi bir şekilde karşılanan, 2.68% cari getiriye sahip, temettü ödeyen bir şirkettir.

Anahtar bilgiler

2.7%

Temettü verimi

n/a

Geri Alım Getirisi

Toplam Hissedar Getirisin/a
Gelecekteki Temettü Verimin/a
Temettü Büyümesi13.5%
Bir sonraki temettü ödeme tarihin/a
Eski temettü tarihin/a
Hisse başına temettüNT$2.500
Ödeme oranı79%

Son temettü ve geri alım güncellemeleri

SciVision Biotech's (TWSE:1786) Upcoming Dividend Will Be Larger Than Last Year's

Jul 22
SciVision Biotech's (TWSE:1786) Upcoming Dividend Will Be Larger Than Last Year's

SciVision Biotech (TWSE:1786) Has Announced That It Will Be Increasing Its Dividend To NT$2.50

Jun 28
SciVision Biotech (TWSE:1786) Has Announced That It Will Be Increasing Its Dividend To NT$2.50

Recent updates

Is Now The Time To Put SciVision Biotech (TWSE:1786) On Your Watchlist?

Oct 11
Is Now The Time To Put SciVision Biotech (TWSE:1786) On Your Watchlist?

SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings

Aug 30
SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings

SciVision Biotech's (TWSE:1786) Upcoming Dividend Will Be Larger Than Last Year's

Jul 22
SciVision Biotech's (TWSE:1786) Upcoming Dividend Will Be Larger Than Last Year's

SciVision Biotech (TWSE:1786) Has Announced That It Will Be Increasing Its Dividend To NT$2.50

Jun 28
SciVision Biotech (TWSE:1786) Has Announced That It Will Be Increasing Its Dividend To NT$2.50

SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings

Jun 14
SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings

SciVision Biotech (TWSE:1786) Seems To Use Debt Rather Sparingly

Jun 04
SciVision Biotech (TWSE:1786) Seems To Use Debt Rather Sparingly

Some Shareholders Feeling Restless Over SciVision Biotech Inc.'s (TWSE:1786) P/E Ratio

Apr 01
Some Shareholders Feeling Restless Over SciVision Biotech Inc.'s (TWSE:1786) P/E Ratio

Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

Apr 20
Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

SciVision Biotech (TPE:1786) Is Looking To Continue Growing Its Returns On Capital

Apr 02
SciVision Biotech (TPE:1786) Is Looking To Continue Growing Its Returns On Capital

Can You Imagine How SciVision Biotech's (TPE:1786) Shareholders Feel About The 33% Share Price Increase?

Mar 15
Can You Imagine How SciVision Biotech's (TPE:1786) Shareholders Feel About The 33% Share Price Increase?

Read This Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend

Feb 25
Read This Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend

Could The Market Be Wrong About SciVision Biotech Inc. (TPE:1786) Given Its Attractive Financial Prospects?

Feb 05
Could The Market Be Wrong About SciVision Biotech Inc. (TPE:1786) Given Its Attractive Financial Prospects?

Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

Jan 18
Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

Will The ROCE Trend At SciVision Biotech (TPE:1786) Continue?

Jan 01
Will The ROCE Trend At SciVision Biotech (TPE:1786) Continue?

SciVision Biotech (TPE:1786) Shareholders Booked A 80% Gain In The Last Three Years

Dec 14
SciVision Biotech (TPE:1786) Shareholders Booked A 80% Gain In The Last Three Years

Key Things To Consider Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend

Nov 25
Key Things To Consider Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: 1786 10 yıldan az bir süredir temettü ödüyor ve bu süre zarfında ödemeler dalgalı oldu.

Büyüyen Temettü: 1786 şirketinin temettü ödemeleri artmış, ancak şirket yalnızca 9 yıldır temettü ödemiştir.


Piyasaya Karşı Temettü Getirisi

SciVision Biotech Piyasaya Karşı Temettü Getirisi
1786 temettü verimi piyasa ile karşılaştırıldığında nasıldır?
SegmentTemettü Verimi
Şirket (1786)2.7%
Pazarın Alt %25'i (TW)1.7%
Pazarın En İyi %25'i (TW)4.5%
Sektör Ortalaması (Medical Equipment)2.9%
Analist tahmini (1786) (3 yıla kadar)n/a

Önemli Temettü: 1786 'in temettüsü ( 2.68% ), TW piyasasındaki temettü ödeyenlerin en alttaki %25'inden ( 1.73% ) daha yüksektir.

Yüksek Temettü: 1786 'in temettüsü ( 2.68% ), TW piyasasındaki temettü ödeyenlerin en üst %25'ine ( 4.45% ) kıyasla düşüktür.


Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Mevcut ödeme oranı ( 79% ) ile 1786 'un ödemeleri kazançlarla karşılanmaktadır.


Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Mevcut nakit ödeme oranı ( 78.8% ) ile 1786 'un temettü ödemeleri nakit akışları tarafından karşılanmaktadır.


Güçlü temettü ödeyen şirketleri keşfedin